Detail akcie Exagen Rg online

Business Summary: Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Exagen Inc revenues increased 19% to $49.9M. Net loss increased 35% to $15.3M. Revenues reflect Commercial segment increase of 19% to $26.5M, Client segment increase of 28% to $11.7M. Higher net loss reflects Selling, general & administrative exp increase of 14% to $33.1M (expense), Interest Exp-Net of Capitalized Interest increase of 79% to $3M (expense).